Indaptus Therapeutics, Inc. (INDP): Business Model Canvas [Apr-2026 Updated]

You're looking at Indaptus Therapeutics, Inc. (INDP) right now, a clinical-stage biotech whose entire near-term fate hinges on its Decoy20 asset, and honestly, the numbers tell a clear story about their operational reality as of late 2025. As of September 30th, they are running on approximately \$5.8 million in cash, while burning through about \$1.52 million just on Research and Development in Q3 2025, so runway management and capital raising are absolutely central to their Key Activities. Their value proposition-a novel, multi-targeted activation of immunity-is compelling, but the Revenue Streams are currently zero product sales, relying instead on equity financing to fund the critical Phase 1b/2 trial execution; to truly understand how this engine is structured, from their reliance on CROs to their investor base, you need to see the full Business Model Canvas breakdown below.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Key Partnerships

You're looking at the external relationships Indaptus Therapeutics, Inc. relies on to move Decoy20 through clinical development and secure necessary funding as of late 2025. These partnerships are critical because, as a clinical-stage biotech, Indaptus Therapeutics doesn't manufacture everything in-house or fund trials solely through operations; they need specialized external help and capital partners.

Clinical Research Organizations (CROs) for Phase 1b/2 trial execution

Indaptus Therapeutics initiated its Phase 1b/2 combination study evaluating Decoy20 with the PD-1 checkpoint inhibitor tislelizumab in August 2025. The execution of this trial relies on external clinical infrastructure, though specific CRO names aren't public in the latest filings. What is concrete is the patient progress: as of the Third Quarter 2025 results reported on November 12, 2025, the company had completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab.

Academic and major oncology centers for clinical trial sites

The clinical trial sites are where the actual patient testing happens. While specific site names aren't detailed here, the collaboration structure is evident through the combination partner. Indaptus Therapeutics entered a clinical supply agreement with BeiGene Switzerland GmbH in October 2024 to advance the evaluation of Decoy20 in combination with their PD-1 checkpoint inhibitor, tislelizumab. This partnership is key to testing Decoy20's synergy in a controlled setting.

• Clinical supply agreement established with BeiGene Switzerland GmbH in October 2024.
• Combination cohort dosing with tislelizumab began in August 2025.
• Pre-clinical data showed significant anti-tumor synergy with a PD-1 inhibitor.

Investment banks/Placement Agents (e.g., Paulson) for capital raising

Securing non-dilutive funding is a constant partnership requirement. Paulson Investment Company, LLC has been consistently involved as the exclusive placement agent for Indaptus Therapeutics' financing activities. You can see the scale of these recent capital events:

The notes issued in June 2025 converted into common stock and warrants in July 2025. The involvement of Paulson Investment Company, LLC signals professional support for these financial initiatives.

Potential future strategic partners for Decoy20 co-development/licensing

The clinical supply agreement with BeiGene Switzerland GmbH for combination trials represents the first step toward broader co-development or licensing. The company's stated outlook for 2025 includes actively pursuing opportunities to expand the applications of its Decoy platform, which suggests ongoing, though likely confidential, discussions for future strategic alliances beyond the current tislelizumab combination trial.

Suppliers of materials for drug manufacturing and formulation

Indaptus Therapeutics' platform relies on proprietary, attenuated and killed, non-pathogenic, Gram-negative bacteria. While the search results confirm the nature of the material-multi-immune agonist bacteria-no specific contract manufacturing organization (CMO) or raw material supplier names or associated costs for the manufacturing and formulation of Decoy20 are publicly disclosed as of late 2025. The company has established state-of-the-art research and development facilities to support process development, preclinical evaluation, and future clinical manufacturing, suggesting some internal capability.

Finance: draft 13-week cash view by Friday.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Key Activities

You're managing a clinical-stage biotech, so the key activities revolve around the lab, the clinic, and the bank. Indaptus Therapeutics, Inc. (INDP) is definitely focused on moving Decoy20 through trials while keeping the lights on. Here's the quick math on what they were actively driving as of late 2025.

Research and Development (R&D) of Decoy20 and pipeline candidates

The core activity is advancing the lead candidate, Decoy20, which is a novel immunotherapy based on killed, multi-immune agonist bacteria. Pre-clinical work continues to support pipeline expansion, showing Decoy product candidates have produced single-agent activity against chronic Hepatitis B virus (HBV) and chronic HIV infection in pre-clinical humanized mouse models. This dual focus-oncology and infectious disease-is a key part of their R&D strategy.

The financial commitment to this work is clear in the reported expenses for the nine months ended September 30, 2025, where Research and development expenses totaled approximately $6.5 million. For the third quarter alone, R&D expenses were approximately $1.52 million, up from $1.47 million in the same period in 2024.

Execution and management of the Decoy20 Phase 1b/2 clinical trial

Managing the Decoy20 Phase 1b/2 combination trial with the PD-1 checkpoint inhibitor tislelizumab is paramount. This activity involves careful monitoring of safety and efficacy data to determine the next steps for enrollment.

As of the Q3 2025 update, Indaptus Therapeutics completed the Safety Lead-In cohort, dosing six evaluable participants with the combination. The Safety Review Committee found the combination tolerable at the current dose and schedule. Still, enrollment has been paused pending additional efficacy evaluations of the remaining participants.

Here's a snapshot of the initial safety cohort results:

Intellectual Property (IP) portfolio expansion and maintenance globally

Protecting the platform technology is a constant, necessary activity. Indaptus Therapeutics actively works to expand and maintain its global IP footprint to secure its novel approach to immune activation.

Significant recent activity included expanding the patent portfolio in China, Japan, and Israel during the first quarter of 2025. This builds on earlier validation, such as the notice of allowance received in September 2021 for the patent covering methods of treatment for infections using bacteria, which provides broad protection for their platform.

Key IP-related activities include:

• Filing, prosecuting, enforcing, and defending patent claims.
• Securing protection for the Decoy20 candidate and platform technology.
• Maintaining existing granted patents globally.

Continuous capital raising and investor relations management

Given the cash burn associated with clinical development, securing financing is a non-stop key activity. The company must manage investor expectations while executing fundraising to extend its operational runway.

Indaptus Therapeutics has been active in raising capital throughout 2025 to support its operations into the first quarter of 2026. The company reported cash and cash equivalents of approximately $5.8 million as of September 30, 2025.

Recent financing milestones include:

• Raised approximately $2.3 million in gross proceeds via its at-the-market facility in September 2025.
• Completed the conversion of promissory notes issued in June 2025 for $5.7 million into common stock and warrants in July 2025.
• Raised $3.2 million through stock and warrant sales in Q1 2025 financing activities.

The net cash used in operating activities for the nine months ended September 30, 2025, was approximately $11.6 million, showing the ongoing need for external capital.

Regulatory filings and communications with health authorities

Interacting with health authorities like the FDA and Health Canada is critical for trial progression. This involves submitting amendments and responding to queries based on emerging clinical data.

The company is focused on communicating trial progress to stakeholders. Management stated they expect to share more data from the combination trial by the end of the year (2025). Furthermore, the Founder and Chief Scientific Officer was scheduled to present at the 3rd Donor Selection & Cell Source Summit on November 19-20, 2025, detailing new research on the Decoy platform.

Regulatory and communication milestones include:

• Completing the Safety Lead-In cohort review by the Safety Review Committee.
• Planning to share combination trial data by the end of 2025.
• Submitting an amendment to Health Canada to initiate the Combination Study in Canada (as planned in early 2025 filings).

Finance: draft 13-week cash view by Friday.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Key Resources

You're looking at the core assets Indaptus Therapeutics, Inc. needs to execute its strategy, and honestly, for a clinical-stage biotech, that means intellectual property and cash runway are king. The foundation here is definitely the platform itself.

The primary hard asset is the Proprietary Decoy20 platform technology and related patents. This patented technology is built from single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria. These bacteria are engineered to act as a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The design goal is to reduce intravenous toxicity while largely keeping the ability to prime or activate innate and adaptive immunity cells. Preclinical work also showed meaningful single-agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections.

Liquidity is always a critical resource, and as of September 30, 2025, Indaptus Therapeutics, Inc. held cash and cash equivalents of approximately $5.8 million. This figure improved sequentially from earlier in the year, supported by financing activities including an at-the-market facility raise of approximately $2.3 million in September 2025. Management guided that this cash position supports ongoing operating activities into the first quarter of 2026. Here's the quick math on the recent operating burn:

The Scientific and clinical management team expertise provides the human capital to advance this complex technology. This team includes key figures driving the current strategy and data generation.

• CEO Jeffrey Meckler, who commented on the company's financial health and execution.
• Founder and Chief Scientific Officer Dr. Michael Newman, who presented on the Decoy platform at the November 2025 Donor Selection & Cell Source Summit.
• Chief Medical Officer Dr. Roger Waltzman, who provided updates on the INDP-D101 clinical trial.

Finally, the Clinical data from the Decoy20 monotherapy and combination cohorts serves as the tangible proof of concept. This data is what validates the platform's mechanism of action in humans. What this estimate hides is that efficacy signals are still being evaluated, so data quality is paramount.

• Monotherapy: Induced a clear reduction in size of liver metastases, consistent with a Partial Response in one patient.
• Combination (Decoy20 + tislelizumab): Safety Lead-In cohort dosed six evaluable participants.
• Combination Safety Review Committee judged the combination tolerable at the current dose and schedule.
• Of the first three evaluable combination patients, one achieved stable disease, and two had disease progression. Enrollment is paused pending further efficacy review.
• Pharmacodynamic data showed weekly Decoy20 treatment triggered broad, blood-based immune cell trafficking.

Finance: draft 13-week cash view by Friday.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Value Propositions

You're looking at the core promise of Indaptus Therapeutics, Inc. (INDP) as they push Decoy20 through clinical trials. The value proposition here isn't about current revenue-which analysts forecast at $0 for 2025-it's about the potential of a fundamentally different approach to immunotherapy.

Novel, multi-targeted activation of both innate and adaptive immunity

The patented Decoy platform is built on using attenuated and killed, non-pathogenic, Gram-negative bacteria. This is designed to safely prime and/or activate multiple immune pathways simultaneously, specifically hitting Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR), and Stimulator of interferon genes (STING) pathways. This simultaneous activation is a key differentiator, aiming to overcome limitations seen when only targeting one part of the immune response.

Potential for broad anti-tumor and anti-viral activity

The platform's potential spans both oncology and infectious diseases, based on preclinical data. The company's investment in R&D reflects this breadth, with Q3 2025 R&D expenses reported at approximately $1.52 million.

• Meaningful single-agent activity against chronic hepatitis B virus (HBV) in pre-clinical models.
• Meaningful single-agent activity against chronic human immunodeficiency virus (HIV) in pre-clinical models.
• Single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas pre-clinically.
• Single-agent eradication of established antigen-expressing breast carcinoma pre-clinically.

Decoy20's tolerability profile in the combination Safety Lead-In cohort

The initial clinical data from the combination trial is where you see the platform's immediate value in a real-world setting. The Safety Lead-In cohort of the Phase 1b/2 trial, combining Decoy20 with the PD-1 inhibitor tislelizumab, has been completed. The Safety Review Committee reviewed the data and determined the combination appears tolerable at the current dose and schedule.

Here's a snapshot of that initial combination safety data as of the Q3 2025 update:

Differentiated mechanism from traditional checkpoint inhibitors

Traditional checkpoint inhibitors, like PD-1/PD-L1 blockers, primarily focus on releasing the brakes on the adaptive immune system. Indaptus Therapeutics' approach is designed to step in earlier and more broadly, providing the initial activation signal. This synergy is what they are testing with tislelizumab.

Potential to treat multiple solid tumor types

The platform is being tested in advanced solid tumors, and the preclinical work suggests a wide applicability. The company's cash position as of September 30, 2025, was approximately $5.8 million, which management expects will support operations into the first quarter of 2026, contingent on disciplined execution of the current trial plan.

• The Phase 1b/2 trial evaluates Decoy20 in combination with tislelizumab for advanced solid tumors.
• Preclinical models included hepatocellular carcinomas and non-Hodgkin's lymphomas.
• The technology is described as antigen-agnostic.

Finance: draft 13-week cash view by Friday.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Customer Relationships

You're looking at how Indaptus Therapeutics, Inc. (INDP) manages its connections with the outside world-investors, doctors, and regulators. For a clinical-stage biotech, these relationships are the lifeblood, directly tied to capital access and trial success. It's a high-stakes game of transparency and progress reporting.

High-touch, direct relationship with institutional and retail investors

The relationship with investors is managed through frequent, mandated disclosures and targeted outreach. You see this play out in the financing activities required to keep the lights on and the trials moving. For instance, in the third quarter of 2025, Indaptus Therapeutics, Inc. raised approximately $2.3 million through its at-the-market facility in September 2025, following a significant $5.7 million conversion of promissory notes to equity in July 2025. This direct engagement is crucial, especially when the cash position, which stood at approximately $5.8 million as of September 30, 2025, is guided to support operations only into the first quarter of 2026. The sentiment among institutional holders can shift quickly; in the second quarter of 2025, while 1 institutional investor added shares, 14 decreased their positions, with VANGUARD GROUP INC removing 9,152 shares. Also, General and administrative expenses for Q3 2025 decreased to $1.1 million from $1.7 million in Q3 2024, partly due to lower investor relations costs. That's the cost of keeping the story alive.

Transparent communication of clinical trial progress via press releases and SEC filings

Indaptus Therapeutics, Inc. relies heavily on press releases and SEC filings to communicate milestones, which directly impacts investor confidence and valuation. The progress on the Decoy20 + tislelizumab combination trial is the primary narrative driver. You can track the financial impact alongside the clinical updates:

The net cash used in operating activities for the nine months ended September 30, 2025, was approximately $11.6 million. Transparency means showing the good and the challenging; for example, the Q3 data showed mixed efficacy with three participants achieving stable disease out of six evaluable patients, leading to enrollment being paused pending efficacy evaluations.

Close collaboration with Key Opinion Leaders (KOLs) and clinical investigators

Collaboration with the medical community is essential for trial execution and scientific validation. The Phase 1b/2 combination study with tislelizumab is a direct result of such collaboration. The Safety Review Committee determined the combination was tolerable at the current dose and schedule after the six-participant Safety Lead-In cohort was completed. Furthermore, the scientific leadership is actively engaging the broader KOL community; Founder and Chief Scientific Officer Dr. Michael Newman was scheduled to present preclinical research on the Decoy bacterial platform at the Donor Selection & Cell Source Summit on November 19-20, 2025. You need to watch for data presentations at these key medical forums.

• Dosed first patient in Phase 1b/2 combination trial in Q2 2025.
• Safety Review Committee confirmed tolerability post-Safety Lead-In.
• Preclinical data presentation scheduled for November 2025.
• The company is working to increase the number of trial sites to accelerate enrollment.

Regulatory engagement with the FDA and other health agencies

Regulatory milestones unlock the next stage of development and market access. Indaptus Therapeutics, Inc. secured key approvals that directly affect their ability to expand clinical reach. Specifically, the company received Clinical Trial authorization from Health Canada, clearing the path for expansion of clinical trial sites. On the intellectual property front, which underpins regulatory exclusivity, the company expanded its patent portfolio in China, Japan, and Israel during the first quarter of 2025. This proactive IP strategy supports future commercialization discussions with potential partners or regulatory bodies.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Channels

The channels Indaptus Therapeutics, Inc. (INDP) uses to reach investors, the scientific community, and trial sites are centered on regulatory disclosures and targeted scientific engagement.

Investor relations presentations and quarterly earnings calls

Investor communication channels include formal corporate presentations and mandatory financial reporting. CEO Jeffrey A. Meckler delivered a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, with a webcast replay available for approximately 90 days.

Financial and operational updates are channeled through SEC filings, such as the 10-Q filed on November 12, 2025, covering the quarter ended September 30, 2025.

Key financial metrics communicated via these channels for the third quarter of 2025 include:

Financing activities are also communicated through these channels; for instance, the company raised approximately $2.3 million through its at-the-market facility in September 2025.

Scientific conferences (e.g., oncology, immunotherapy symposiums) for data dissemination

Data dissemination occurs at specialized scientific meetings. Founder and Chief Scientific Officer Dr. Michael Newman presented at the 3rd Donor Selection & Cell Source Summit on November 19-20, 2025, in San Diego, California.

The company anticipates sharing more data from its combination trial by the end of the year (2025).

Key scientific communication points include:

• Preclinical data showed Decoy20 activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) in in vivo models.
• The May 2025 corporate presentation projected Combo Proof of Concept data in late 2025 / early 2026.
• The Safety Lead-In cohort dosed six evaluable participants with the Decoy20 and tislelizumab combination.
• Three participants achieved stable disease at the first assessment following the Safety Lead-In cohort completion.

Peer-reviewed journal publications of pre-clinical and clinical data

The channel for peer-reviewed journal publications is utilized for formal validation of pre-clinical and clinical data, though specific publication titles or dates in late 2025 are not detailed here.

Direct communication with clinical trial sites and patient advocacy groups

Direct engagement is necessary for trial execution and patient support. The company completed the Safety Lead-In cohort, which involved dosing six evaluable participants.

The Investor & Media Relations contact email listed for direct inquiries is investors@indaptusrx.com.

SEC filings (10-Q, 8-K) for financial and operational updates

The primary formal channel for operational updates includes filings like the 8-K filed on November 12, 2025, reporting the Q3 2025 earnings release.

Balance sheet strength as of September 30, 2025, showed cash and cash equivalents of approximately $5.8 million, expected to support operations into the first quarter of 2026.

Operational updates also included the July 2025 completion of the conversion of promissory notes issued in June 2025, totaling $5.7 million, into common stock, pre-funded warrants, and warrants.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Customer Segments

As a seasoned analyst, I see the customer segments for Indaptus Therapeutics, Inc. (INDP) as a tiered structure, moving from the capital providers to the ultimate end-users of the therapy.

Institutional and retail investors funding the current operations

The immediate customer base is the capital market, which has provided necessary liquidity to sustain operations through the late stages of 2025. You need to understand the recent capital structure to gauge the dilution risk and runway.

Indaptus Therapeutics, Inc. executed several financing activities to maintain development. For the nine months ended September 30, 2025, net cash provided by financing activities was approximately $11.7 million. This included a January 2025 financing where the company received $2,246,500 from 16 investors pursuant to Regulation D. More recently, in July 2025, the company raised an aggregate of $5.7 million in gross proceeds through convertible promissory notes and warrants, which were subsequently converted to equity in July 2025. These notes carried a 6% annual interest rate and were set to mature on July 28, 2026. Furthermore, approximately $2.3 million was raised via an at-the-market facility in September 2025. As of September 30, 2025, the cash and equivalents balance stood at approximately $5.8 million, guiding runway into Q1 2026.

Hedge fund activity shows mixed sentiment among institutional players:

• In Q1 2025, 6 institutional investors added shares, while 8 decreased positions.
• By Q3 2025, 4 institutional investors added shares, but 13 decreased positions.
• For the most recent reported quarter (Q3 2025), 1 institutional investor added shares, and 14 decreased positions.

Future pharmaceutical/biotech companies seeking licensing or acquisition targets

This segment represents potential strategic partners or acquirers, attracted by the platform technology and clinical progress. The company's stated focus is on pioneering innovative cancer and viral infection treatments, which is the core asset these entities would value.

The company continues to assess all financing options that would support its corporate strategy, which explicitly excludes any business development activities that may be undertaken. The Decoy platform has seen recent patent approvals in China, Japan, and Israel, which strengthens the intellectual property base for potential licensing or acquisition discussions.

Oncologists and clinical investigators for trial enrollment and future adoption

These are the medical professionals critical for validating the therapy and driving future prescription volume. Their engagement is measured by trial participation and site activation.

The clinical development pipeline is centered on the lead candidate, Decoy20. As of the Q3 2025 report, the Safety Lead-In cohort of the Phase 1b/2 combination study with tislelizumab was completed, dosing six evaluable participants. Enrollment in this specific combination arm was paused pending further efficacy evaluations. Prior to this, the company had enrolled 32 patients in the weekly dosing monotherapy trials. A key operational development for investigator reach was receiving clinical trial authorization from Health Canada in February 2025, allowing expansion of the ongoing U.S. trial to Canadian sites.

• Phase 1b/2 Combination Trial Dosing (Decoy20 + Tislelizumab): 6 participants evaluated.
• Prior Weekly Dosing Enrollment (Decoy20 Monotherapy): 32 patients enrolled to date.
• Geographic Expansion: Authorization received from Health Canada in February 2025.

Patients with advanced solid tumors and certain viral infections (ultimate beneficiaries)

These are the individuals who will ultimately receive the therapeutic benefit of the company's technology. Their segmentation is based on the target diseases for the Decoy platform.

Indaptus Therapeutics, Inc. is focused on developing therapies for two primary areas: oncology and infectious diseases. The lead candidate, Decoy20, is currently being tested in a Phase 1 clinical trial specifically targeting patients with advanced solid tumors. Beyond oncology, the company's broader platform technology has shown potential for viral infections, with recent patent approvals specifically aimed at combination therapies for Hepatitis B and HIV.

The company's technology is designed to be systemically-administered, which is a key feature for broad patient applicability across these indications.

Finance: draft 13-week cash view by Friday.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Indaptus Therapeutics, Inc.'s operations as of late 2025. For a clinical-stage biotech, the cost structure is heavily weighted toward discovery and trials. Here's the quick math on the major outflows for the third quarter ended September 30, 2025.

The primary cost drivers are clearly R&D and G&A, which together form the bulk of the operating expenses. Total quarterly operating expenses for Q3 2025 were reported at $2.65 million.

The key quarterly cost components for Indaptus Therapeutics, Inc. are detailed below:

• Research and Development (R&D) expenses were approximately $1.52 million in Q3 2025.
• General and Administrative (G&A) expenses were approximately $1.1 million in Q3 2025.

To give you a fuller picture of the burn rate leading up to this point in 2025, here is a comparison of the nine-month figures:

Costs associated with clinical trial execution and manufacturing are embedded within the R&D figures, reflecting the progression of the lead candidate, Decoy20. The increase in R&D expense for the nine months ended September 30, 2025, over the prior year was largely due to clinical trial activity. Still, disciplined management of other areas helped offset some of that trial cost increase.

• Increase in R&D due to ongoing Phase 1 study for the nine months ended September 30, 2025: approximately $2.6 million.
• Increase in R&D due to ongoing Phase 1 study for Q3 2025: approximately $0.35 million.
• Decrease in payroll and related expenses and stock-based compensation partially offset R&D increases by approximately $0.9 million (nine months) and $0.3 million (Q3 2025).

Legal and professional fees for IP and regulatory compliance are captured within the G&A fluctuations. For Q3 2025, professional fees specifically caused an increase in G&A of approximately $0.1 million, which was part of the overall G&A spend of $1.1 million. The G&A decrease year-over-year was primarily driven by a reduction of approximately $0.7 million in stock-based compensation, payroll, board fees, investor relations costs, and D&O insurance policy costs in Q3 2025.

Capital raising costs are reflected in the transaction-related expenses from financing activities completed earlier in 2025. The company raised approximately $2.3 million through its at-the-market facility in September 2025. Furthermore, the conversion of promissory notes issued in June 2025 for $5.7 million occurred in July 2025. Transaction-related expenses associated with the private placement of convertible notes in June 2025 contributed an increase of approximately $0.9 million to G&A expenses for the nine-month period.

Here is a breakdown of the Q3 2025 G&A components that influenced the $1.1 million total:

The cash position as of September 30, 2025, was approximately $5.8 million.

Indaptus Therapeutics, Inc. (INDP) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Indaptus Therapeutics, Inc. (INDP) as of late 2025, and honestly, it's what you expect for a company deep in clinical development. The reality is that for a clinical-stage biotech like Indaptus Therapeutics, Inc., the primary source of cash inflow isn't selling a product; it's selling ownership or debt instruments.

Current primary revenue is from equity and debt financing activities. This is the lifeblood that funds the expensive research and development, particularly the ongoing Phase 1 clinical trial for Decoy20. As of the third quarter ended September 30, 2025, the company has been actively managing its capital structure to extend its runway, which was projected into the first quarter of 2026 based on current plans.

The most recent capital infusion directly supporting operations came in September 2025. Specifically, Indaptus Therapeutics, Inc. achieved gross proceeds of approximately $2.3 million raised via ATM in September 2025. This capital, raised through their at-the-market facility, was a key component of their financing strategy for the nine months ending September 30, 2025.

To give you a clearer picture of the financing landscape that constitutes their current revenue, here's a look at the major capital-raising events through Q3 2025:

This financing activity is crucial because, as a pre-revenue entity, operating expenses are high. Net cash used in operating activities for the nine months ended September 30, 2025, was approximately $11.6 million, largely driven by R&D expenses, which totaled approximately $6.5 million over the same nine-month period.

Looking ahead, the real upside revenue potential for Indaptus Therapeutics, Inc. lies entirely outside of current sales. You need to track their progress in securing strategic partnerships, as this is the standard path to commercialization and significant non-dilutive funding for a company at this stage.

Future potential revenue streams are centered on:

• Future potential revenue from licensing or collaboration agreements with large pharma. This would involve out-licensing Decoy20 for specific indications or geographies, providing an upfront cash payment.
• Future potential milestone payments from development partnerships. These are contingent payments triggered by achieving specific clinical or regulatory goals, such as successful completion of a Phase 2 trial or an FDA filing.

It is important to note the current state: Zero product revenue as a pre-revenue, clinical-stage company. Analysts forecasting revenue for 2025 reflect this, with the consensus estimate for Indaptus Therapeutics, Inc.'s revenue in 2025 being $0. The company is entirely dependent on its current cash position and its ability to access capital markets or secure a deal to fund its path through the combination trial and beyond.

Finance: draft next 13-week cash view incorporating the September ATM proceeds by Monday.